Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Sector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit

Thu, 31st Jan 2013 15:04

The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices.The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at constant exchange rates (CER) from $33.59bn to $27.97bn due to a loss of exclusivity on several brands. Core earnings per share (EPS) dropped 9.0% from $7.28 to $6.41.Furthermore, the firm said it expects a "mid-to-high single digit percentage decline" in revenue at CER this year. Meanwhile, core EPS will decline "significantly more" than revenue due to higher operating costs.Analyst Savvas Neophytou from Panmure Gordon said that consensus estimates for 2013 would likely come down. He maintained a 'hold' rating for AstraZeneca.With the stock having had a good run recently, Neophytou said that shares are "up with events" for the moment, with the discount to the European pharmaceutical sector justified given "perceived increased forecast risk". AIM-listed medial company Scancell was in the red after reporting an operating loss of £0.99m in its first half, slightly worse than the year before.Veterinary pharmaceutical group Dechra was also lower after appointing a new Chief Financial Officer. Anne-Francoise Nesmes will join the company in April from GlaxoSmithKline where she has worked since 1997 in a number of finance roles including Senior Vice-President, Finance of Vaccines in Belgium. However, a strong rise from FTSE 250 specialist healthcare business BTG did limit losses in the sector, after the company said that full-year revenues would likely be at the 'top end' of guidance.BTG said the last three months have wielded positive results, particularly from acute care items. The board now anticipates revenues for the year to March 31st to reach the higher point of its estimate between £205m to £215m. Top performing sectors so far todayBeverages 14,079.42 +1.61%Construction & Materials 3,757.56 +1.45%Oil Equipment, Services & Distribution 25,125.83 +1.36%Forestry & Paper 8,073.13 +1.22%Mining 20,242.12 +0.95%Bottom performing sectors so far todayPharmaceuticals & Biotechnology 10,070.84 -1.13%Oil & Gas Producers 8,244.19 -1.11%Software & Computer Services 989.53 -1.06%Industrial Metals & Mining 2,974.72 -0.91%Chemicals 8,874.18 -0.86%BC

Related Shares

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.